Table 2.
The ISTs of phage therapy since 2017 acquired from Clinicaltrials.gov.
| Name | Phase | Adm route | Target | Indication | Starting year | Developer | Country | NCT. Id |
|---|---|---|---|---|---|---|---|---|
| Preforpro | 3 | Oral | NS | Vaginal infection | May 1, 2023 (est) | Deerland Enzymes | United Kingdom | NCT05590195 |
| Pyobacteriophage | 3 | IH | Multiple common bacteria | Acute tonsillitis | October 2, 2020 | Tashkent Pediatric Medical Institute | Uzbekistan | NCT04682964 |
| LBP-EC01 | 2/3 | IU & IV | E. coli | Urinary tract infection | July 13, 2022 | Locus Bioscience | United States | NCT05488340 |
| AP-PA02 | 2 | IH | P. aeruginosa | Chronic pulmonary infection | January 10, 2023 | Armata Pharmaceuticals, Inc. | United States | NCT05616221 |
| PhageBank | 2 | NS | S. aureus | Diabetic foot osteomyelitis | November 24, 2021 | Adaptive Phage Therapeutics, Inc. | United States | NCT05177107 |
| PhageBank | 2 | IO | Multiple common bacteria | Chronic prosthetic join infection on hip/knee | March 27, 2023 | Adaptive Phage Therapeutics, Inc. | United States | NCT05269134 |
| PP1493 & PP1815 | 2 | IA | S. aureus | Prosthetic joint infection | June 15, 2022 | Pherecydes Pharma | France | NCT05369104 |
| YPT-01 | 1/2 | IH | P. aeruginosa | Cystic fibrosis infection | March 29, 2021 | Yale University | United States | NCT04684641 |
| BACTELIDE | 1/2 | Topical/IH | S. aureus, P. aeruginosa, or K. pneumoniae | Pressure ulcer infection | January, 2022 (est.) | Phagelux Inc. | United States | NCT04815798 |
| PhageBank | 1/2 | IO & IV | Multiple common bacteria | Chronic prosthetic join infection on hip/knee | May, 2022 (est.) | Adaptive Phage Therapeutics, Inc. | United States | NCT05269121 |
| BX005-A | 1/2 | Topical | S. aureus | Atopic dermatitis | May 2022 (est.) | BiomX | United States | NCT05240300 |
| ShigActive | 1/2 | Oral | Shigellosis | Experimental Shigella challenge | February 23, 2023 | Intralytix | United States | NCT05182749 |
| EcoActive | 1/2 | Oral | E. coli | Crohn’s Diseases | May 1, 2019 | Intralytix | United States | NCT03808103 |
| VRELysin | 1/2 | Oral | Enterococcus | Intestinal infection | April 1, 2023 (est.) | Intralytix | United States | NCT05715619 |
| NS | 1/2 | Topical | S. aureus | Diebetic foot ulcers infection | June 1, 2022 (est.) | Center Hospitalier Universitaire de Nîmes | France | NCT02664740 |
| TP-102 | 1/2 | Topical | P. aeruginosa, S. aureus, A. baumanni | Diabetic foot ulcer infection | March 22, 2021 | Technophage | Israel | NCT04803708 |
| WRAIR-PAM-CF1 | 1/2 | IV | P. aeruginosa | Cystic fibrosis infection | October 3, 2022 | National Institute of Allergy and Infectious Diseases | United States | NCT05453578 |
| AP-PA02 | 1/2 | IH | P. aeruginosa | Chronic lung infection | December 22, 2020 | Armata Pharmaceuticals, Inc. | United States | NCT04596319 |
| AP-SA02 | 1/2 | IV | S. aureus | Bacteremia | April 26, 2022 | Armata Pharmaceuticals, Inc. | United States | NCT05184764 |
| BX004-A | 1/2 | IH | P. aeruginosa | Chronic pulmonary infection | June 21, 2022 | BiomX, Inc. | United States | NCT05010577 |
| PGX-0100 | 1 | IH | S. aureus, P. aeruginosa, or K. pneumoniae | Burn infection | January 2022 (est.) | Phagelux Inc. | Australia | NCT04323475 |
| BX002-A | 1 | Oral | NA | NA—Healthy individual | October 28, 2020 | BiomX, Inc. | United States | NCT04737876 |
| SNIPR001 | 1 | Oral | NA | NA—Healthy individual | March 24, 2022 | SNIPR Biome Aps. | United Kingdom | NCT05277350 |
| PrePhage | 1 | Nasal | NS | Necrotizing Enterocolitis in Preterm infant | April 1, 2023 (est.) | Rigshospitalet Hospital | Denmark | NCT05272579 |
*Clinical trials that are canceled, discontinued, or have entered a new phase are not included. Information is up to date since the last check on June 25, 2023. NA, Not applicable; NS, Non-specified; Adm. route, Route of administration; NCT Id., Clinical Trial register ID; IV, Intravenous; IH, Inhalation; IO, Intraoperative; IU, Intraurethral/intravesical; and IA, Intra-articular injection.